

Special Issue

Recent Advances in Drug Therapy for Malaria

Message from the Guest Editors

Despite significant efforts, malaria continues to be a health problem in sub-Saharan Africa and claims hundreds of thousands of victims yearly, mainly children under the age of five. Artemisinin combination therapy has been the cornerstone of antimalarial therapy in the last two decades, but the emergence of artemisinin resistance in *P. falciparum* poses a challenge for continuing to reduce malaria incidence and mortality globally. The first malaria vaccine has been recommended by the WHO since October 2021 for children aged five months and older living in areas with moderate to high malaria transmission. New therapeutic strategies remain essential to avoid malaria deaths in the coming years. In addition, drugs with preventive and transmission-blocking effects are crucial to take the next step towards eliminating malaria. This Special Issue aims to publish original research and review articles related to the prevention, treatment, and transmission blocking of malaria to assemble a collection of publications highlighting recent advances in drug therapy for malaria and to raise awareness of this life-threatening disease.

Guest Editors

Dr. Jana Held

Institute of Tropical Medicine, University of Tübingen, 72074 Tübingen, Germany

Prof. Dr. Steffen Borrmann

Institute of Tropical Medicine, University of Tübingen, 72074 Tübingen, Germany

Deadline for manuscript submissions

closed (31 August 2023)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/151323

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).